ARIA To Face FDA In April, OPXA's Woes Continue, Keep An Eye On OPHT

Shares of Opexa Therapeutics Inc. (OPXA), which took a beating on Abili-T trial results last week, slumped further on Monday - touching a new 52-week low.

from RTT - Biotech http://ift.tt/2fzfSK0
via IFTTT